HOUSTON, Oct. 08, 2024 — Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced the initiation of … Continue reading Bio-Path Holdings (NASDAQ:BPTH) Initiates Development of Therapeutic Program for Treatment of Obesity